ClinicalTrials.gg
RecruitingNCT04913649AGE-ANEMIAUpdated Apr 27, 2026

Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients

A Phase 4 interventional study of Ferric Derisomaltose 100 MG/ML and Sodium chloride in Iron Deficiency Anemia, sponsored by dr. P. Noordzij. Recruiting at 2 sites in Netherlands. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by dr. P. Noordzij · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 8 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Planned enrollment
7th of 32
310 · median 121
Started
2021
with 2 others
Phase 4
7 of 32
3 open now
Registered
21st of 32
by date
Lead sponsor
1 of 32
dr. P. Noordzij

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 7th largest by planned enrollment, is one of 3 that started in 2021, is one of 7 in phase 4, and was the 21st registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

8 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

Postoperative anemia is common in cardiac surgery with cardiopulmonary bypass. Iron deficiency delays the recovery from postoperative anemia and may negatively affect the postoperative trajectory of cardiac surgery patients. The objective of the study is to determine the effect of treatment of postoperative iron deficiency anemia with intravenous iron on disability 90 days after surgery. This will be evaluated in a randomized placebo-controlled double blind two-center trial in which 310 elective cardiac surgery patients will be included.

Read the detailed description

Rationale: Postoperative anemia is common in cardiac surgery with cardiopulmonary bypass. Iron deficiency delays the recovery from postoperative anemia and may negatively affect the postoperative trajectory of cardiac surgery patients.

Objective: To determine the effect of treatment of postoperative iron deficiency anemia (IDA) with intravenous iron (IVI) on disability 90 days after surgery.

Study design: Randomized placebo-controlled double blind two-center trial

Study population: 310 elderly patients (≥70 years) with moderate postoperative IDA on postoperative day (POD) 1 (hemoglobin (Hb) 85 - 110 g/L, ferritin concentration \< 100 µg/L or iron saturation \<20%) after uncomplicated elective cardiac surgery (aortic valve repair (AVR) and coronary artery bypass graft (CABG) surgery).

Intervention: Postoperative treatment with a single dose IVI (ferric derisomaltose, Monofer®, N = 155) compared to postoperative treatment with sodium chloride (NaCL) 0.9% (placebo, N = 155).

Main study endpoints: Primary endpoint is disability as measured by the 12- item World Health Organization Disability Assessment score 2.0 (WHODAS-12 at POD 90 after elective cardiac surgery. Secondary endpoints are change in patient reported outcome measures (PROMs) related to dyspnea (assessed with the Rose Dyspnea Score (RDS)) and to health-related quality of life (HRQL) (assessed with The Older Persons and Informal Caregivers-Short Form (TOPICS-SF) questionnaire) at POD 90, the number of postoperative red blood cell (RBC) transfusions, change in reticulocyte hemoglobin content (pg) from randomization to hospital discharge, Hb levels at discharge, hospital complications and days alive and out of hospital at 90 days. Lastly, the difference in functional outcomes (e.g. steep ramp or 6-minute walk test) and Hb value at POD 90 will be assessed as an exploratory endpoint.

03

Conditions studied

  • Iron Deficiency Anemia

Keywords

  • Cardiac surgery
  • Postoperative anemia
  • Intravenous iron
  • Postoperative disability
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mentally competent with age ≥ 70 years
  • Elective AVR or CABG surgery
  • Expected uncomplicated postoperative trajectory, defined as:
  • No inotropic agents or ventilation at time of final inclusion (POD 1)
  • Expected discharge to general ward at POD 1
  • Moderate postoperative IDA, defined as:
  • between 85 and 110 g/L and
  • Ferritin \<100 µg/L or
  • Iron saturation (TSAT) \< 20%

Exclusion criteria

Exclusion Criteria:

  • Medical history of iron overload/haemochromatosis
  • Medical history of liver cirrhosis or /AST value in blood serum triple of normal value (female patients: ALT >120, AST >105 U/L. Male patients: ALT>150, AST>135 U/L)
  • Severe renal failure (\<15ml/min/1.73m2)
  • Recent treatment with IVI (\<12 weeks prior)
  • Serious or severe allergic reaction to IVI in medical history
  • Severe asthma or eczema in medical history (atopic constitution)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    Intravenous iron (ferric derisomaltose)

    The intervention consists of a single dose of ferric derisomaltose (Monofer®) 100 mg/mL solution for infusion (Monofer® is a registered product with a marketing authorization in the Netherlands (RVG number: 103070). Manufacturer: Pharmacosmos A/S, Denmark. Dutch marketing authorization holder: Cablon Medical B.V). The method of administration and dosage of the investigational medication are standard treatment. The ferric derisomaltose dose will calculated for each patient depending on body weight (20mg/kg) and diluted in 250 ml NaCl 0.9%. Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards

    Drug: Ferric Derisomaltose 100 MG/ML

  • Placebo comparator
    Placebo

    Single dose of sodium chloride 0.9% (250ml). Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards

    Drug: Sodium chloride

Interventions

  • DrugFerric Derisomaltose 100 MG/ML

    Drug page: Iron isomaltoside 1000Studies of Iron isomaltoside 1000Iron isomaltoside 1000 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Postoperative treatment with a single dose IVI (ferric derisomaltose), with a dose of 20mg/kg in approximately 60 minutes.

    Also known as: Monofer

  • DrugSodium chloride

    Postoperative treatment with a single dose NaCl 0.9% in approximately 60 minutes.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Disability

    Disability measured by the 12- item World Health Organization Disability Assessment score 2.0 (WHODAS-12). Based on the answers a disability score can be calculated. 0% is no disability and 100% is fully disabled.

    Time frame: 90 days after elective cardiac surgery

Secondary outcomes

  1. Change in patient reported outcome measures (PROMs) related to dyspnea

    PROMS related to dyspnea are assessed with the Rose Dyspnea Scale (RDS). Rose Dyspnea Scale scores range from 0 to 4 with higher scores indicating more dyspnea with common activities.

    Time frame: 90 days after elective cardiac surgery

  2. Change in patient reported outcome measures (PROMs) related to health related quality of life (HRQL)

    HRQL is assessed with The Older Persons and Informal Caregivers-Short Form (TOPICS-SF) questionnaire. The TOPIC-SF is comprised of 22 items in 7 domains of health and well-being. Scores in the different domains ranges from 0 to 5, higher scores indicating diminished quality of life.

    Time frame: 90 days after elective cardiac surgery

  3. Red blood cell transfusions

    Number of red blood cell transfusions during hospital stay

    Time frame: +/- 7 days after elective cardiac surgery

  4. Change in reticulocyte hemoglobin content

    Change in reticulocyte hemoglobin content from randomization to hospital discharge

    Time frame: +/- 7 days after elective cardiac surgery

  5. Change in Hb level

    Change in Hb level from randomization to hospital discharge

    Time frame: +/- 7 days after elective cardiac surgery

  6. Postoperative complications

    Postoperative complications during hospital stay

    Time frame: +/- 7 days after elective cardiac surgery

  7. Days alive and out of hospital

    Days alive and out of hospital

    Time frame: 90 days after elective cardiac surgery

Other outcomes

  1. Functional outcome (exploratory endpoint)

    As part of routine care, patients are offered a cardiac revalidation program supervised by a physical therapist after hospital discharge (POD 90). To assess whether patients can safely start exercising, a functional test is performed (e.g. steep ramp or 6-minute walk test). For this study, the results of these tests will be requested to assess functional capacity after surgery

    Time frame: +/- 90 days after elective cardiac surgery

  2. Change in Hb level at 90 days (exploratory endpoint)

    Laboratory results (i.e. Hb values if available) assessed by the treating cardiologist are requested when patients have visited the hospital during follow-up

    Time frame: +/- 90 days after elective cardiac surgery

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Smoor RM, Rettig TCD, Vernooij LM, Groenewegen EM, van Dongen HPA, Noordzij PG. The effect of postoperative intravenous iron in anaemic, older cardiac surgery patients on disability-free survival (AGE ANEMIA study): study protocol for a multi-centre, double-blind, randomized, placebo-controlled trial. Trials. 2023 Oct 26;24(1):693. doi: 10.1186/s13063-023-07725-y. PubMed 37885026 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Nov 2026, 62 months after the start.

Of 43 non-industry phase 4 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's planned 62 months is above that.

Counting every sponsor, half of 51 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 4, 2021
StartActual
Sep 23, 2021
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04913649
Lead sponsor
dr. P. Noordzij
Collaborators
Pharmacosmos A/S
Responsible party
dr. P. Noordzij (Principal investigator, St. Antonius Hospital) — Sponsor-investigator
First posted
Jun 4, 2021
Start date
Sep 23, 2021
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 27, 2026

Study contacts

Peter Noordzij, MD, PhD
Contact
p.noordzij@antoniusziekenhuis.nl
883203000 ext. + 31 (0)
Rosa Smoor, MD
Contact
r.smoor@antoniusziekenhuis.nl
883203000 ext. + 31 (0)
Peter Noordzij, MD, PhD
principal investigator · St. Antonius Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion